Navigation Links
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Date:8/19/2007

Company on Target to File Supplemental New Drug Application in the Fourth

Quarter

FRAZER, Pa., Aug. 16 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced positive results from a 12-week, Phase 3 clinical trial of FENTORA(R) (fentanyl buccal tablet) [C-II] in patients with breakthrough pain associated with a broad range of chronic non-cancer pain conditions. The study achieved statistical significance on the primary endpoint. Results across the 12 weeks of treatment showed both statistically significant and clinically relevant outcomes for patients with breakthrough pain who were already receiving and who were tolerant to opioid therapy for their underlying persistent pain. FENTORA is approved only for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

"We are excited to complete our Phase 3 program with this third and final controlled study. These data show similar positive outcomes as those with FENTORA in treating breakthrough pain in opioid-tolerant patients with cancer, chronic neuropathic pain, and chronic low-back pain," said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations. "We plan to submit these data to the Food and Drug Administration in the fourth quarter as part of our supplemental New Drug Application."

About the Study

The double-blind, placebo-controlled, variable dose Phase 3 trial included 148 patients. The primary endpoint was the Sum of Pain Intensity Differences from five to 60 minutes (SPID(60)) as assessed after 12 weeks of treatment. SPID(60) is a measure that assesses analgesic efficacy of a pain medication over the first 60 minutes after treatment. Patients treated with FENTORA showed a statistically significant improvement on the primary endpoint (p<0.0001) compared with placebo. FENTORA was general
'/>"/>

SOURCE Cephalon, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Cambridge Semantics, the leading provider of ... that 2014 was a record-breaking year across the board for ... Anzo Smart Data Platform and our Smart Data solutions, our ... diverse data which led to record growth for the company ...
(Date:1/22/2015)... 2015 Crystal Diagnostics (CDx) Xpress System, a ... received AOAC-PTM Certifications for the six non-O157 Shiga toxin-producing E. ... referred to as STEC or the “Big-6”) as well as ... (cfu) per 325 g of raw ground beef and raw ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Dr. Greg Leyer ... 12th annual Scripps Natural Supplements Pre-Conference seminar on probiotics in ... is an annual continuing education conference for health care professionals. ... included the topic of probiotics in health. Dr. Leyer spoke ...
(Date:1/22/2015)... Denville, NJ (PRWEB) January 22, 2015 ... shearing technologies such as the Bioruptor® and complete ... semi-automation system for chromatin immunoprecipitation, alleviating the need ... reagents and controls needed for ChIP of histones ...
Breaking Biology Technology:Cambridge Semantics Announces Record Results for 2014 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2
... DIEGO, Dec. 12, 2011  Receptos Inc. announced today the ... Ltd. (Osaka, Japan) for the research and development ... coupled receptor (GPCR) target. Under the terms of ... platform to produce high resolution protein crystal structures ...
... Dec. 12, 2011  Stemline Therapeutics, Inc. today announced that ... scheduled to present at the Oppenheimer 22nd Annual Healthcare ... ET at the Waldorf Astoria Hotel in New York ... Stemline Therapeutics, Inc. is a clinical stage ...
... 12, 2011 Silence Therapeutics plc ... interference ( RNAi ) therapeutics company, announces that the United ... of four key RNAi patents that form part of the ... by an anonymous third party during 2010, the USPTO has ...
Cached Biology Technology:Receptos and Ono Establish Collaboration with Focus on Bioactive Lipid Discovery Research 2Receptos and Ono Establish Collaboration with Focus on Bioactive Lipid Discovery Research 3Stemline Therapeutics, Inc. to Present at the Oppenheimer 22nd Annual Healthcare Conference 2Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents 2Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents 3Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents 4
(Date:1/22/2015)... 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased ... State of Washington,s Department of Licensing, ... and central issuance system for driver,s licenses and identification cards ... planning and development will start in January 2015, with enrollment ...
(Date:1/22/2015)... Jan. 15, 2015  BellBrook Labs, a leader in ... the launch of a TR-FRET (time resolved Forster ... UDP Assay, a high throughput screening assay for ... will allow for sensitive detection of hundreds of ...
(Date:1/22/2015)... NEW YORK , Jan. 21, 2015  Analyst Report Issued ... Credit Card Brands report showed that planet-wide, transactions at merchants ... 2011, while the total number of credit, debit, and prepaid ... the U.S. were victims of fraudulent card usage in 2012, ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... 2012 - Every process in a cell is affected ... the human body and their relationship to diseases is ... therapies. The Ontario Genomics Institute (OGI) is providing $100,000 ... University of Toronto (U of T),s Mammalian Membrane Two-Hybrid ...
... Predicting how atherosclerosis, osteoporosis or cancer will progress ... difficult. In a new study, researchers took another ... able to predict from a blood sample the ... diseasesa specific person would produce. This ...
... for medical and biological research, but are difficult to study ... from adults may provide a path to study stem cells ... JoVE ( Journal of Visualized Experiments ), details ... cells in the peripheral blood. The technique has been ...
Cached Biology News:Ontario Genomics Institute invests in validation of a novel protein interaction technology at U of T 2Researchers use blood testing to predict level of enzymes that facilitate disease progression 2Novel technique to produce stem cells from peripheral blood 2
Reported to support murine B lymphocytes, hematopoietic tissue from bone marrow, B cells stimulated with lipopolysaccharide, T lymphocytes, and a variety of hybrid cells....
... F-12 was developed for culturing hybrid cells ... modification consists of doubling the amino acids ... salt concentrations have been altered as well. ... per liter, which may render it unsuitable ...
... Alsevers solution is an isotonic, balanced salt ... preservative, which permits the storage of whole blood ... usage, an equal volume of blood is collected ... but thoroughly, mixed. The solution is placed in ...
... or individual RNA sequences from high throughput synthesis ... RNAs from LC Sciences. These products provide a ... of DESIGNED sequences delivered in a microtube as ... a single verified RNA sequence. This is a ...
Biology Products: